An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Detailed price information for Vir Biotechnology Inc (VIR-Q) from The Globe and Mail including charting and trades.

The consensus estimate for Q4 2025 revenue is $23.18 million, and the earnings are expected to come in at -$0.41 per share. The full year 2025's revenue is expected to be $19.22 million, and the ...

Vir has a promising pipeline, and expects to report data this year on several phase 2 clinical trials. Vir's revenue rose by 133.4% last year. The Food and Drug Administration recently made a decision ...

Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s prostate cancer candidate VIR-5500 through a collaboration that could generate more than $1.7 billion for the San ...

GSK is walking away from a core piece of its $345 million bet on Vir Biotechnology. The partners have ended their collaboration on anti-influenza antibodies, freeing Vir to “actively” pitch the ...

Despite interest from GSK and high hopes of leading the next generation of influenza A prophylaxis, Vir Biotechnology’s monoclonal antibody has failed its first phase 2 challenge. The PENINSULA study ...

Vir signed a “landmark” collaboration with Astellas to advance VIR-5500, receiving $315 million upfront ( $240M cash + $75M equity) and becoming eligible for up to $1.37 billion in milestones, with a ...

UKRAINE - 2022/01/23: In this photo illustration, a Vir Biotechnology logo is seen on a smartphone and a computer screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) ...